Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06805630 · ClinicalTrials.gov registry record · NA

Urine Methylation Markers in UTUC

A NA study of Upper Tract Urothelial Cancer, sponsored by Duke University.

Recruiting
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT06805630: Recruiting NA study of Upper Tract Urothelial Cancer, sponsored by Duke University.

NCT06805630 is a NA study of Upper Tract Urothelial Cancer that is actively recruiting participants, run by Duke University. The registered enrollment target is 50 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06805630, a NA study of Upper Tract Urothelial Cancer, is actively recruiting participants, sponsored by Duke University.

RECRUITING
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

This is a research study to measure DNA markers in the urine of patients with upper tract urothelial cancer (UTUC) before surgery and during follow-up visits. Identifying these DNA markers could improve diagnosis before surgery, help assess risk, and predict early recurrence of the cancer. Urine samples will be de-identified and sent to Pangea Laboratory LLC for analysis. The results of this test will be compared to the traditional tests in upper tract urothelial cancer, such as cells in the urine and tissue biopsy.

Interventions

  • DIAGNOSTIC_TEST Bladder CARE™

Study Locations (1)

North Carolina

  • Duke University - Durham

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2025-05-07
Est. Completion 2026-06
Phase NA
Duke University

1,725 total trials

What NCT06805630 shows while recruiting

NCT06805630 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Upper Tract Urothelial Cancer appearing as the primary indexed condition, and to 1 intervention - of which Bladder CARE™ is the first listed.

NCT06805630 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT06805630 about?

NCT06805630 is a clinical study titled "Urine Methylation Markers in UTUC". This is a research study to measure DNA markers in the urine of patients with upper tract urothelial cancer (UTUC) before surgery and during follow-up visits. Identifying these DNA markers could improve diagnosis before surgery, help assess risk, and predict early recurrence of the cancer. Urine sam...

What is the current status of trial NCT06805630?

This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2025-05-07. Estimated completion is 2026-06.

What conditions does trial NCT06805630 study?

This clinical trial studies the following conditions: Upper Tract Urothelial Cancer.

What interventions are being tested in trial NCT06805630?

The interventions under investigation include: Bladder CARE™ (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT06805630?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06805630 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT06805630's enrollment target sits among peer trials

50 1280th of 2000 higher than 622 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06805630, the US trial registry maintained by the National Library of Medicine. NCT06805630 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.